Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE -- Ignore unavailable to you. Want to Upgrade?

To: larry larsen who wrote (352)	4/29/1998 8:16:00 PM
From: Susan Saline	Read Replies (1) \| Respond to of 670

Hi all, re: no re-action actually I was glad there was no re-action. Usually when a company is the acquirer, their stock price drops, whereas the company being acquired stock price goes up. In this instance the acquired company is private though. so in retrospect the price not going down is a good thing. bottom line ... earnings will grow Growth causes the stock price to appreciate. Next Q earnings will cause this stock to rally nicely. remember though, there will be a 1.5 ml. write off, but this should not affect the eps. 3 months down the road, patience will preside. New people here... did you buy for a quick day trade? And get stuck? consider yourself lucky...at least this company has a plan and a future. long, Sue

To: larry larsen who wrote (352)	4/30/1998 10:45:00 AM
From: Peter H. Proctor	Read Replies (1) \| Respond to of 670

" But, what are you referring to re: in 44 liquormart and Supreme Court rulings? " The rules have changed WRT the FDA's ability to prevent "true" drug claims, particularly for agents that are currently "legal products". This includes cosmetic formulations ( Procyute just bought a private label manufacturer ) and off-label uses for approved drugs. E.g., Months before Merck got FDA-approval for Finasteride as a hair-growth remedy, they were out wining and dining docs ( including me ) promoting this off-label use. My understanding is that now the FDA has to jump thru hoops, have their officials sit for depositions ( the unkindest blow of all ), etc. BTW, the ex-FDA commissoner David Kessler actually refused a court order to sit for a deposition in a related case ( WLF v. Kessler ). None of these guys wants to be put to the question under oath. No more arbitrary decisions made behind closed doors. About time too. The drug firms seem to have figured this out and are acting accordingly, tho nobody seems to be making a big deal about it. Don't ask, don't tell, etc. Dr. P